Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Practice Guidelines

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Novel lipid-lowering therapies, including PCSK9 inhibitors and ezetimibe, offer effective strategies for LDL-C reduction.
• Clinical practice guidelines are essential for integrating these therapies into patient care.

Purpose of the Study:

• To develop a clinical practice guideline for the use of PCSK9 inhibitors and ezetimibe.
• To provide risk-stratified recommendations for reducing cardiovascular events.
• To guide clinicians in optimizing lipid management for patients at various cardiovascular risk levels.

Main Methods:

• Systematic review of randomized controlled trials and meta-analyses evaluating PCSK9 inhibitors and ezetimibe.
• Development of recommendations based on GRADE (Grading of Recommendations, Development and Evaluation) methodology.
• Consideration of patient values, preferences, and resource implications.

Main Results:

• PCSK9 inhibitors and ezetimibe significantly reduce LDL-C levels and cardiovascular events in high-risk populations.
• Risk-stratified recommendations are provided for initiating and intensifying therapy.
• The guideline addresses specific patient subgroups, including those with familial hypercholesterolemia and statin intolerance.

Conclusions:

• PCSK9 inhibitors and ezetimibe are valuable additions to the therapeutic armamentarium for cardiovascular event reduction.
• Tailoring treatment based on individual cardiovascular risk is crucial for maximizing benefits.
• Adherence to these guidelines can improve patient outcomes and reduce the burden of cardiovascular disease.